335 related articles for article (PubMed ID: 32325459)
1. The Multifaceted Nature of Tumor Microenvironment in Breast Carcinomas.
Annaratone L; Cascardi E; Vissio E; Sarotto I; Chmielik E; Sapino A; Berrino E; Marchiò C
Pathobiology; 2020; 87(2):125-142. PubMed ID: 32325459
[TBL] [Abstract][Full Text] [Related]
2. [Pathological features and immune microenvironment in HER-2 intratumoral heterogeneous breast cancers].
Yang YL; Song YM; Xue HQ; Sun H; Li YQ; Qian XL; Jiao J; Li KP; Zhang H; Guo XJ
Zhonghua Zhong Liu Za Zhi; 2023 Feb; 45(2):165-169. PubMed ID: 36781238
[No Abstract] [Full Text] [Related]
3. Comparison of the tumor immune microenvironment phenotypes in different breast cancers after neoadjuvant therapy.
Han M; Li J; Wu S; Wu C; Yu Y; Liu Y
Cancer Med; 2023 Feb; 12(3):2906-2917. PubMed ID: 36073303
[TBL] [Abstract][Full Text] [Related]
4. Prognostic and predictive impacts of tumor-infiltrating lymphocytes differ between Triple-negative and HER2-positive breast cancers treated with standard systemic therapies.
Hida AI; Sagara Y; Yotsumoto D; Kanemitsu S; Kawano J; Baba S; Rai Y; Oshiro Y; Aogi K; Sagara Y; Ohi Y
Breast Cancer Res Treat; 2016 Jul; 158(1):1-9. PubMed ID: 27260189
[TBL] [Abstract][Full Text] [Related]
5. Identification of an immune-suppressed subtype of feline triple-negative basal-like invasive mammary carcinomas, spontaneous models of breast cancer.
Dagher E; Simbault L; Abadie J; Loussouarn D; Campone M; Nguyen F
Tumour Biol; 2020 Jan; 42(1):1010428319901052. PubMed ID: 31959092
[TBL] [Abstract][Full Text] [Related]
6. Heterogeneity of tumour-infiltrating lymphocytes in breast cancer and its prognostic significance.
Althobiti M; Aleskandarany MA; Joseph C; Toss M; Mongan N; Diez-Rodriguez M; Nolan CC; Ashankyty I; Ellis IO; Green AR; Rakha EA
Histopathology; 2018 Dec; 73(6):887-896. PubMed ID: 29947077
[TBL] [Abstract][Full Text] [Related]
7. The balance between breast cancer and the immune system: Challenges for prognosis and clinical benefit from immunotherapies.
Baxevanis CN; Fortis SP; Perez SA
Semin Cancer Biol; 2021 Jul; 72():76-89. PubMed ID: 31881337
[TBL] [Abstract][Full Text] [Related]
8. A subset of activated fibroblasts is associated with distant relapse in early luminal breast cancer.
Bonneau C; Eliès A; Kieffer Y; Bourachot B; Ladoire S; Pelon F; Hequet D; Guinebretière JM; Blanchet C; Vincent-Salomon A; Rouzier R; Mechta-Grigoriou F
Breast Cancer Res; 2020 Jul; 22(1):76. PubMed ID: 32665033
[TBL] [Abstract][Full Text] [Related]
9. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial.
Loi S; Michiels S; Salgado R; Sirtaine N; Jose V; Fumagalli D; Kellokumpu-Lehtinen PL; Bono P; Kataja V; Desmedt C; Piccart MJ; Loibl S; Denkert C; Smyth MJ; Joensuu H; Sotiriou C
Ann Oncol; 2014 Aug; 25(8):1544-50. PubMed ID: 24608200
[TBL] [Abstract][Full Text] [Related]
10. An immune stratification reveals a subset of PD-1/LAG-3 double-positive triple-negative breast cancers.
Bottai G; Raschioni C; Losurdo A; Di Tommaso L; Tinterri C; Torrisi R; Reis-Filho JS; Roncalli M; Sotiriou C; Santoro A; Mantovani A; Loi S; Santarpia L
Breast Cancer Res; 2016 Dec; 18(1):121. PubMed ID: 27912781
[TBL] [Abstract][Full Text] [Related]
11. The CD4/CD8 ratio of tumor-infiltrating lymphocytes at the tumor-host interface has prognostic value in triple-negative breast cancer.
Wang K; Shen T; Siegal GP; Wei S
Hum Pathol; 2017 Nov; 69():110-117. PubMed ID: 28993275
[TBL] [Abstract][Full Text] [Related]
12. Genomic alterations affecting tumor-infiltrating lymphocytes and PD-L1 expression patterns in triple-negative breast cancer.
Wang H; Ding XH; Liu CL; Xiao Y; Shui RH; Li YP; Chen C; Yang WT; Liu S; Chen CS; Shao ZM; Jiang YZ
J Natl Cancer Inst; 2023 Dec; 115(12):1586-1596. PubMed ID: 37549066
[TBL] [Abstract][Full Text] [Related]
13. Immune infiltrates in the breast cancer microenvironment: detection, characterization and clinical implication.
Burugu S; Asleh-Aburaya K; Nielsen TO
Breast Cancer; 2017 Jan; 24(1):3-15. PubMed ID: 27138387
[TBL] [Abstract][Full Text] [Related]
14. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
Denkert C; von Minckwitz G; Darb-Esfahani S; Lederer B; Heppner BI; Weber KE; Budczies J; Huober J; Klauschen F; Furlanetto J; Schmitt WD; Blohmer JU; Karn T; Pfitzner BM; Kümmel S; Engels K; Schneeweiss A; Hartmann A; Noske A; Fasching PA; Jackisch C; van Mackelenbergh M; Sinn P; Schem C; Hanusch C; Untch M; Loibl S
Lancet Oncol; 2018 Jan; 19(1):40-50. PubMed ID: 29233559
[TBL] [Abstract][Full Text] [Related]
15. Tumor-Infiltrating Lymphocytes/Plasmocytes in Chemotherapeutically Non-Influenced Triple-Negative Breast Cancers - Correlation with Morphological and Clinico-Pathological Parameters.
Kolečková M; Kolář Z; Ehrmann J; Kořínková G; Zlámalová N; Melichar B; Trojanec R
Klin Onkol; 2019; 32(5):380-387. PubMed ID: 31610672
[TBL] [Abstract][Full Text] [Related]
16. Tumor microenvironment in triple-negative breast cancer: the correlation of tumor-associated macrophages and tumor-infiltrating lymphocytes.
Kuroda H; Jamiyan T; Yamaguchi R; Kakumoto A; Abe A; Harada O; Masunaga A
Clin Transl Oncol; 2021 Dec; 23(12):2513-2525. PubMed ID: 34089486
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of tumor-infiltrating B lymphocytes and plasma cells in triple-negative breast cancer.
Kuroda H; Jamiyan T; Yamaguchi R; Kakumoto A; Abe A; Harada O; Enkhbat B; Masunaga A
Breast Cancer; 2021 Jul; 28(4):904-914. PubMed ID: 33629216
[TBL] [Abstract][Full Text] [Related]
18. Predictive biomarkers of response to immunotherapy in triple-negative breast cancer - state of the art and future perspectives.
Tancoš V; Blichárová A
Klin Onkol; 2023; 36(1):28-34. PubMed ID: 36868830
[TBL] [Abstract][Full Text] [Related]
19. Identification of stromal ColXα1 and tumor-infiltrating lymphocytes as putative predictive markers of neoadjuvant therapy in estrogen receptor-positive/HER2-positive breast cancer.
Brodsky AS; Xiong J; Yang D; Schorl C; Fenton MA; Graves TA; Sikov WM; Resnick MB; Wang Y
BMC Cancer; 2016 Apr; 16():274. PubMed ID: 27090210
[TBL] [Abstract][Full Text] [Related]
20. Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials.
Dieci MV; Mathieu MC; Guarneri V; Conte P; Delaloge S; Andre F; Goubar A
Ann Oncol; 2015 Aug; 26(8):1698-704. PubMed ID: 25995301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
